Test drug target for Alzheimer’s or memory loss
Part of Brain & nervous system, Mental health clinical trials.
This Phase 2 study looks at how well a medicine that targets DAO (an enzyme in the body) helps people with Alzheimer’s disease or mild cognitive impairment. You may be considered if your memory symptoms are mild to moderate and you meet specific brain-function and symptom scoring rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Alzheimer’s disease or mild cognitive impairment (memory problems).
- Your memory/mental testing score (MMSE) is between 10 and 26.
- Your clinician’s severity rating (CDR) is 0.5 or 1.
- You do not have signs suggesting stroke-related dementia (Hachinski score 4 or less).
- You do not have substance abuse or dependence.
- You do not have Parkinson’s disease, epilepsy, or dementia with hallucinations/psychotic features.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether adding omega-3 and an “NMDA support” treatment can improve or slow symptoms in early Alzheimer’s disease or mild cognitive impairment. It may help by supporting brain signaling involved in memory and thinking.
This study looks at how well people with Alzheimer’s disease (AD) or mild cognitive impairment (MCI) perform on standardized memory/brain tests. It may help researchers understand changes over time, and whether certain types of brain signals or test results track with the condition.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This trial tests a new combination treatment (DAOIB and an antioxidant) for people with early Alzheimer's or mild cognitive impairment. It aims to see if the treatment can help slow or improve memory and thinking problems.
This Phase 2 trial tests DAOIB to improve “brain fog” and thinking problems that happen after COVID-19. You may be screened if your symptoms started after a COVID infection and have lasted for months, and if your health tests are normal.
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
Hear when a new Dementia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.